Anticancer carrier-linked prodrugs in clinical trials

被引：75

作者：

Kratz, Felix ^{[1
]}

Abu Ajaj, Khalid ^{[1
]}

Warnecke, Andre ^{[1
]}

机构：

[1] Tumor Biol Ctr, Macromol Prodrugs, D-79106 Freiburg, Germany

来源：

EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2007年 / 16卷 / 07期

关键词：

antibodies; anticancer prodrugs; cancer chemotherapy; drug targeting; polymer therapeutics;

D O I：

10.1517/13543784.16.7.1037

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Coupling of low molecular weight anticancer drugs to antibodies, serum proteins or polymers through a cleavable linker has been an effective method for improving the therapeutic index of cytotoxic established agents. Modern drug-antibody conjugates that have recently entered clinical trials have primarily used highly potent drugs such as calicheamicin or maytansins. Gemtuzumab ozogamicin, a conjugate of calicheamicin and an anti-CD33 humanized antibody, is the first drug-antibody conjugate to receive market approval. Drug conjugates that have undergone clinical assessment include N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugates with doxorubicin, camptothecin, paclitaxel and Pt(II) complexes, poly(ethylene glycol) conjugates with camptothecin and paclitaxel, polyglutamate conjugates with paclitaxel and camptothecin, a methotrexate-albumin conjugate and an albumin-binding doxorubicin prodrug. This review summarizes the Phase I - III studies that have been performed with these macromolecular prodrugs.

引用

页码：1037 / 1058

页数：22

共 82 条

[51] A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin [J].

Schoemaker, NE ;

van Kesteren, C ;

Rosing, H ;

Jansen, S ;

Swart, M ;

Lieverst, J ;

Fraier, D ;

Breda, M ;

Pellizzoni, C ;

Spinelli, R ;

Porro, MG ;

Beijnen, JH ;

Schellens, JHM ;

Huinink, WWT .

BRITISH JOURNAL OF CANCER, 2002, 87 (06) :608-614

[52]

Scott LC, 2004, J CLIN ONCOL, V22, p321S

[53] Hepatic drug targeting: Phase I evaluation of polymer-bound doxorubicin [J].

Seymour, LW ;

Ferry, DR ;

Anderson, D ;

Hesslewood, S ;

Julyan, PJ ;

Poyner, R ;

Doran, J ;

Young, AM ;

Burtles, S ;

Kerr, DJ .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (06) :1668-1676

[54] In vitro and in vivo metabolism of paclitaxel poliglumex: identification of metabolites and active proteases [J].

Shaffer, Scott A. ;

Baker-Lee, Cassie ;

Kennedy, Jacob ;

Lai, Man Shun ;

de Vries, Peter ;

Buhler, Kent ;

Singer, Jack W. .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 59 (04) :537-548

[55] Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: A phase I study of an anti-CD33 calicheamicin immunoconjugate [J].

Sievers, EL ;

Appelbaum, FR ;

Spielberger, RT ;

Forman, SJ ;

Flowers, D ;

Smith, FO ;

Shannon-Dorcy, K ;

Berger, MS ;

Bernstein, ID .

BLOOD, 1999, 93 (11) :3678-3684

[56] Paclitaxel poliglumex (XYOTAX™, CT-2103):: A macromolecular taxane [J].

Singer, JW .

JOURNAL OF CONTROLLED RELEASE, 2005, 109 (1-3) :120-126

[57] Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane [J].

Singer, JW ;

Shaffer, S ;

Baker, B ;

Bernareggi, A ;

Stromatt, S ;

Nienstedt, D ;

Besman, M .

ANTI-CANCER DRUGS, 2005, 16 (03) :243-254

[58]

Smith S, 2001, CURR OPIN MOL THER, V3, P198

[59]

Smith SV, 2005, CURR OPIN MOL THER, V7, P394

[60]

Smith SV, 2004, CURR OPIN MOL THER, V6, P666

← 1 2 3 4 5 6 7 8 9 →